YY1 suppresses FEN1 over-expression and drug resistance in breast cancer
详细信息    查看全文
  • 作者：Jianwei Wang (1)
    Lina Zhou (1) (2)
    Zhi Li (3)
    Ting Zhang (1)
    Wenpeng Liu (1)
    Zheng Liu (2)
    Yate-Ching Yuan (2)
    Fan Su (2)
    Lu Xu (3)
    Yan Wang (3)
    Xiaotong Zhou (3)
    Hong Xu (4)
    Yuejin Hua (4)
    Ying-Jie Wang (5)
    Li Zheng (2)
    Yue-E Teng (3)
    Binghui Shen (2)

    1. College of Life Sciences     ; Zhejiang University ; Hangzhou ; China
    2. Departments of Radiation Biology and Molecular Medicine     ; Beckman Research Institute of City of Hope ; 1500 East Duarte Road ; Duarte ; California ; 91010 ; USA
    3. Departments of Medical Oncology and Thoracic Surgery     ; The First Hospital of China Medical University ; No. 155 North Nanjing Street ; Heping District ; Shenyang ; 110001 ; China
    4. College of Agricultural Sciences and Biotechnology     ; Zhejiang University ; Hangzhou ; China
    5. School of Medicine     ; Zhejiang University ; Hangzhou ; China
  • 关键词：Flap endonuclease 1 (FEN1) ; YY1 ; Over ; expression ; Promoter ; Drug resistance
  • 刊名：BMC Cancer
  • 出版年：2015
  • 出版时间：December 2015
  • 年：2015
  • 卷：15
  • 期：1
  • 全文大小：2,102 KB
  • 参考文献：1. Gottesman, MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: pp. 615-627 CrossRef
    2. Zahreddine, H, Borden, KL (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4: pp. 28 CrossRef
    3. Johannessen, TC, Bjerkvig, R, Tysnes, BB (2008) DNA repair and cancer stem-like cells鈥損otential partners in glioma drug resistance?. Cancer Treat Rev 34: pp. 558-567 CrossRef
    4. Muller, MR, Thomale, J, Rajewsky, MF, Seeber, S (1998) Drug resistance and DNA repair in leukaemia. Cytotechnology 27: pp. 175-185 CrossRef
    5. Salehan, MR, Morse, HR (2013) DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 70: pp. 31-40
    6. Zheng, L, Dai, H, Zhou, M, Li, X, Liu, C, Guo, Z, Wu, X, Wu, J, Wang, C, Zhong, J (2012) Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression. Nat Commun 3: pp. 815 CrossRef
    7. Nikolova, T, Christmann, M, Kaina, B (2009) FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res 29: pp. 2453-2459
    8. Shen, B, Singh, P, Liu, R, Qiu, J, Zheng, L, Finger, LD, Alas, S (2005) Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. Bioessays 27: pp. 717-729 CrossRef
    9. Zheng, L, Jia, J, Finger, LD, Guo, Z, Zer, C, Shen, B (2011) Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res 39: pp. 781-794 CrossRef
    10. Balakrishnan, L, Bambara, RA (2013) Flap Endonuclease 1. Annu Rev Biochem 82: pp. 119-138 CrossRef
    11. Henneke, G, Friedrich-Heineken, E, Hubscher, U (2003) Flap endonuclease 1: a novel tumour suppresser protein. Trends Biochem Sci 28: pp. 384-390 CrossRef
    12. Liu, Y, Kao, HI, Bambara, RA (2004) Flap endonuclease 1: a central component of DNA metabolism. Annu Rev Biochem 73: pp. 589-615 CrossRef
    13. Liu, P, Qian, L, Sung, JS, Souza-Pinto, NC, Zheng, L, Bogenhagen, DF, Bohr, VA, Wilson, DM, Shen, B, Demple, B (2008) Removal of oxidative DNA damage via FEN1-dependent long-patch base excision repair in human cell mitochondria. Mol Cell Biol 28: pp. 4975-4987 CrossRef
    14. Zheng, L, Shen, B (2011) Okazaki fragment maturation: nucleases take centre stage. J Mol Cell Biol 3: pp. 23-30 CrossRef
    15. Zheng, L, Zhou, M, Chai, Q, Parrish, J, Xue, D, Patrick, SM, Turchi, JJ, Yannone, SM, Chen, D, Shen, B (2005) Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Rep 6: pp. 83-89 CrossRef
    16. Saharia, A, Guittat, L, Crocker, S, Lim, A, Steffen, M, Kulkarni, S, Stewart, SA (2008) Flap endonuclease 1 contributes to telomere stability. Curr Biol 18: pp. 496-500 CrossRef
    17. Saharia, A, Stewart, SA (2009) FEN1 contributes to telomere stability in ALT-positive tumor cells. Oncogene 28: pp. 1162-1167 CrossRef
    18. Sampathi, S, Bhusari, A, Shen, B, Chai, W (2009) Human flap endonuclease I is in complex with telomerase and is required for telomerase-mediated telomere maintenance. J Biol Chem 284: pp. 3682-3690 CrossRef
    19. Saharia, A, Teasley, DC, Duxin, JP, Dao, B, Chiappinelli, KB, Stewart, SA (2010) FEN1 ensures telomere stability by facilitating replication fork re-initiation. J Biol Chem 285: pp. 27057-27066 CrossRef
    20. Zheng, L, Dai, H, Zhou, M, Li, M, Singh, P, Qiu, J, Tsark, W, Huang, Q, Kernstine, K, Zhang, X (2007) Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med 13: pp. 812-819 CrossRef
    21. LaTulippe, E, Satagopan, J, Smith, A, Scher, H, Scardino, P, Reuter, V, Gerald, WL (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: pp. 4499-4506
    22. Singh, P, Yang, M, Dai, H, Yu, D, Huang, Q, Tan, W, Kernstine, KH, Lin, D, Shen, B (2008) Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol Cancer Res 6: pp. 1710-1717
    23. Shen, Z (2011) Genomic instability and cancer: an introduction. J Mol Cell Biol 3: pp. 1-3 CrossRef
    24. Miyoshi, T, Nagai, T, Kikuchi, S, Ohmine, K, Nakamura, M, Hanafusa, T, Komatsu, N, Ozawa, K (2007) Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib. Exp Hematol 35: pp. 1358-1365 CrossRef
    25. Sato, M, Girard, L, Sekine, I, Sunaga, N, Ramirez, RD, Kamibayashi, C, Minna, JD (2003) Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. Oncogene 22: pp. 7243-7246 CrossRef
    26. Kim, JM, Sohn, HY, Yoon, SY, Oh, JH, Yang, JO, Kim, JH, Song, KS, Rho, SM, Yoo, HS, Kim, YS (2005) Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11: pp. 473-482
    27. Lam, JS, Seligson, DB, Yu, H, Li, A, Eeva, M, Pantuck, AJ, Zeng, G, Horvath, S, Belldegrun, AS (2006) Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int 98: pp. 445-451 CrossRef
    28. Krause, A, Combaret, V, Iacono, I, Lacroix, B, Compagnon, C, Bergeron, C, Valsesia-Wittmann, S, Leissner, P, Mougin, B, Puisieux, A (2005) Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett 225: pp. 111-120 CrossRef
    29. Christmann, M, Tomicic, MT, Origer, J, Kaina, B (2005) Fen1 is induced p53 dependently and involved in the recovery from UV-light-induced replication inhibition. Oncogene 24: pp. 8304-8313 CrossRef
    30. Kokkinakis, DM, Liu, X, Neuner, RD (2005) Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma. Mol Cancer Ther 4: pp. 1338-1348 CrossRef
    31. Castellano, G, Torrisi, E, Ligresti, G, Malaponte, G, Militello, L, Russo, AE, McCubrey, JA, Canevari, S, Libra, M (2009) The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 8: pp. 1367-1372 CrossRef
    32. Nicholson, S, Whitehouse, H, Naidoo, K, Byers, RJ (2011) Yin Yang 1 in human cancer. Crit Rev Oncog 16: pp. 245-260 CrossRef
    33. Zaravinos, A, Spandidos, DA (2010) Yin yang 1 expression in human tumors. Cell Cycle 9: pp. 512-522 CrossRef
    34. Wang, X, Feng, Y, Xu, L, Chen, Y, Zhang, Y, Su, D, Ren, G, Lu, J, Huang, B (2008) YY1 restrained cell senescence through repressing the transcription of p16. Biochim Biophys Acta 1783: pp. 1876-1883 CrossRef
    35. Gordon, S, Akopyan, G, Garban, H, Bonavida, B (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25: pp. 1125-1142 CrossRef
    36. Deng, Z, Wan, M, Cao, P, Rao, A, Cramer, SD, Sui, G (2009) Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene 28: pp. 3746-3757 CrossRef
    37. Wu, KK (2006) Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol Biol 338: pp. 281-290
    38. Deng, WG, Zhu, Y, Montero, A, Wu, KK (2003) Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem 323: pp. 12-18 CrossRef
    39. Lin, W, Sampathi, S, Dai, H, Liu, C, Zhou, M, Hu, J, Huang, Q, Campbell, J, Shin-Ya, K, Zheng, L (2013) Mammalian DNA2 helicase/nuclease cleaves G-quadruplex DNA and is required for telomere integrity. EMBO J 32: pp. 1425-1439 CrossRef
    40. Lin, Y, Yang, Y, Li, W, Chen, Q, Li, J, Pan, X, Zhou, L, Liu, C, Chen, C, He, J (2012) Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell 48: pp. 627-640 CrossRef
    41. Ivshina, AV, George, J, Senko, O, Mow, B, Putti, TC, Smeds, J, Lindahl, T, Pawitan, Y, Hall, P, Nordgren, H (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: pp. 10292-10301 CrossRef
    42. Bair, E, Tibshirani, R (2004) Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2: pp. E108 CrossRef
    43. Riggs, KJ, Saleque, S, Wong, KK, Merrell, KT, Lee, JS, Shi, Y, Calame, K (1993) Yin-yang 1 activates the c-myc promoter. Mol Cell Biol 13: pp. 7487-7495
    44. Wang, CC, Tsai, MF, Hong, TM, Chang, GC, Chen, CY, Yang, WM, Chen, JJ, Yang, PC (2005) The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene 24: pp. 4081-4093 CrossRef
    45. Lee, MH, Lahusen, T, Wang, RH, Xiao, C, Xu, X, Hwang, YS, He, WW, Shi, Y, Deng, CX (2012) Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene 31: pp. 116-127 CrossRef
    46. Burgess, ST, Shen, C, Ferguson, LA, O鈥橬eill, GT, Docherty, K, Hunter, N, Goldmann, W (2009) Identification of adjacent binding sites for the YY1 and E4BP4 transcription factors in the ovine PrP (Prion) gene promoter. J Biol Chem 284: pp. 6716-6724 CrossRef
    47. Athanikar, JN, Badge, RM, Moran, JV (2004) A YY1-binding site is required for accurate human LINE-1 transcription initiation. Nucleic Acids Res 32: pp. 3846-3855 CrossRef
    48. Atchison, M, Basu, A, Zaprazna, K, Papasani, M (2011) Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects. Crit Rev Oncog 16: pp. 143-161 CrossRef
    49. Huang, E, Cheng, SH, Dressman, H, Pittman, J, Tsou, MH, Horng, CF, Bild, A, Iversen, ES, Liao, M, Chen, CM (2003) Gene expression predictors of breast cancer outcomes. Lancet 361: pp. 1590-1596 CrossRef
    50. Pawitan, Y, Bjohle, J, Amler, L, Borg, AL, Egyhazi, S, Hall, P, Han, X, Holmberg, L, Huang, F, Klaar, S (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: pp. R953-964 CrossRef
    51. Sotiriou, C, Neo, SY, McShane, LM, Korn, EL, Long, PM, Jazaeri, A, Martiat, P, Fox, SB, Harris, AL, Liu, ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: pp. 10393-10398 CrossRef
    52. Wang, Y, Klijn, JG, Zhang, Y, Sieuwerts, AM, Look, MP, Yang, F, Talantov, D, Timmermans, M, Meijer-van Gelder, ME, Yu, J (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: pp. 671-679 CrossRef
    53. Martin, LP, Hamilton, TC, Schilder, RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: pp. 1291-1295 CrossRef
    54. Sarkaria, JN, Kitange, GJ, James, CD, Plummer, R, Calvert, H, Weller, M, Wick, W (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: pp. 2900-2908 CrossRef
    55. Dabholkar, M, Bostick-Bruton, F, Weber, C, Bohr, VA, Egwuagu, C, Reed, E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: pp. 1512-1517 CrossRef
    56. Kang, S, Ju, W, Kim, JW, Park, NH, Song, YS, Kim, SC, Park, SY, Kang, SB, Lee, HP (2006) Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38: pp. 320-324 CrossRef
    57. Olaussen, KA, Dunant, A, Fouret, P, Brambilla, E, Andre, F, Haddad, V, Taranchon, E, Filipits, M, Pirker, R, Popper, HH (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: pp. 983-991 CrossRef
    58. Metzger, R, Leichman, CG, Danenberg, KD, Danenberg, PV, Lenz, HJ, Hayashi, K, Groshen, S, Salonga, D, Cohen, H, Laine, L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: pp. 309-316
    59. Fink, D, Nebel, S, Norris, PS, Baergen, RN, Wilczynski, SP, Costa, MJ, Haas, M, Cannistra, SA, Howell, SB (1998) Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77: pp. 741-746 CrossRef
    60. Strathdee, G, MacKean, MJ, Illand, M, Brown, R (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: pp. 2335-2341 CrossRef
    61. Karran, P, Marinus, MG (1982) Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature 296: pp. 868-869 CrossRef
    62. Yoshioka, K, Yoshioka, Y, Hsieh, P (2006) ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell 22: pp. 501-510 CrossRef
    63. Verbeek, B, Southgate, TD, Gilham, DE, Margison, GP (2008) O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85: pp. 17-33 CrossRef
    64. Sui, G, Affar, B, Shi, Y, Brignone, C, Wall, NR, Yin, P, Donohoe, M, Luke, MP, Calvo, D, Grossman, SR (2004) Yin Yang 1 is a negative regulator of p53. Cell 117: pp. 859-872 CrossRef
    65. Guo, Z, Kanjanapangka, J, Liu, N, Liu, S, Liu, C, Wu, Z, Wang, Y, Loh, T, Kowolik, C, Jamsen, J (2012) Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. Mol Cell 47: pp. 444-456 CrossRef
    66. Affar, B, Gay, F, Shi, Y, Liu, H, Huarte, M, Wu, S, Collins, T, Li, E, Shi, Y (2006) Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol 26: pp. 3565-3581 CrossRef
  • 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
  • 出版者：BioMed Central
  • ISSN：1471-2407
文摘
Background Drug resistance is a major challenge in cancer therapeutics. Abundant evidence indicates that DNA repair systems are enhanced after repetitive chemotherapeutic treatments, rendering cancers cells drug-resistant. Flap endonuclease 1 (FEN1) plays critical roles in DNA replication and repair and in counteracting replication stress, which is a key mechanism for many chemotherapeutic drugs to kill cancer cells. FEN1 was previously shown to be upregulated in response to DNA damaging agents. However, it is unclear about the transcription factors that regulate FEN1 expression in human cancer. More importantly, it is unknown whether up-regulation of FEN1 has an adverse impact on the prognosis of chemotherapeutic treatments of human cancers. Methods To reveal regulation mechanism of FEN1 expression, we search and identify FEN1 transcription factors or repressors and investigate their function on FEN1 expression by using a combination of biochemical, molecular, and cellular approaches. Furthermore, to gain insights into the impact of FEN1 levels on the response of human cancer to therapeutic treatments, we determine FEN1 levels in human breast cancer specimens and correlate them to the response to treatments and the survivorship of corresponding breast cancer patients. Results We observe that FEN1 is significantly up-regulated upon treatment of chemotherapeutic drugs such as mitomycin C (MMC) and Taxol in breast cancer cells. We identify that the transcription factor/repressor YY1 binds to the FEN1 promoter and suppresses the expression of FEN1 gene. In response to the drug treatments, YY1 is dissociated from the FEN1 promoter region leading over-expression of FEN1. Overexpression of YY1 in the cells results in down-regulation of FEN1 and sensitization of the cancer cells to MMC or taxol. Furthermore, we observe that the level of FEN1 is inversely correlated with cancer drug and radiation resistance and with survivorship in breast cancer patients. Conclusion Altogether, our current data indicate that YY1 is a transcription repressor of FEN1 regulating FEN1 levels in response to DNA damaging agents. FEN1 is up-regulated in human breast cancer and its levels inversely correlated with cancer drug and radiation resistance and with survivorship in breast cancer patients.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700